The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

NCT04979611 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the use of a special imaging scan called 68Ga-NOTA-exendin-4 PET/CT to detect insulinomas in people suspected of having this type of pancreatic tumor.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 60 people Planned (estimated).

Who can join Ages 6–70 · all sexes

Timeline Started 2020-08 · est. completion 2025-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04979611 ↗

Description as written by the study sponsor.

The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Treatments tested

68Ga-NOTA-exendin-4 Drug

A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously

Main thing measured	Standard uptake value (SUV)
Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions studied	Insulinoma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04979611 ↗